Rising Prevalence Of Chronic Pain Conditions Fueling The Growth Of The Due To Increasing Demand For Targeted Long-Term Pain Management Is Contributing To Changes In The Neurodegenerative Disorder Therapeutics Market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Neurodegenerative Disorder Therapeutics Market Expected To Change From 2026 To 2030?
The market for neurodegenerative disorder therapeutics has witnessed substantial expansion in recent years. Its value is set to increase from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The previous period’s growth can be attributed to several factors including the rising incidence of neurodegenerative conditions, an expanding aging population, the limited array of available treatments, increasing public understanding of the benefits of early diagnosis, and the improvement of hospital and neurological care infrastructure.
The neurodegenerative disorder therapeutics market is expected to experience significant growth over the next few years, with its size projected to reach $34.13 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This expansion during the forecast period is attributable to the development of gene therapies, progress in monoclonal antibody treatments, the incorporation of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the broader application of personalized medicine and targeted therapeutics. Significant trends for this period encompass the growing adoption of neuroprotective and neurorestorative therapies, a heightened emphasis on symptom management and patient-centric care, an increase in clinical trials for innovative neurodegenerative drugs, the wider use of personalized and targeted therapeutic methods, and the integration of home care and remote monitoring solutions.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
What Key Drivers Are Fueling The Growth Of The Neurodegenerative Disorder Therapeutics Market?
Rising financial allocation towards research and development (R&D) in the field of neurodegenerative disorder therapeutics is projected to fuel the expansion of the neurodegenerative disorder therapeutics market moving ahead. Funding for research and development concerning neurodegenerative disorders is initiated by governmental bodies and organizations due to several strong factors, such as the growing incidence, substantial unaddressed medical requirements, financial implications, worldwide health endeavors, among others. As an illustration, in March 2023, the Government of Canada, a Canada-based federal administration, announced in 2023 a financial commitment of $38.3 million dedicated to furthering research into neurodegenerative diseases. Consequently, an escalating commitment to research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to consistently propel the expansion of the neurodegenerative disorder therapeutics market throughout the projected timeframe.
How Is The Neurodegenerative Disorder Therapeutics Market Organized By Segment Classification?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
What Trends Are Affecting The Direction Of The Neurodegenerative Disorder Therapeutics Market?
Leading companies in the neurodegenerative disorder therapeutics market are concentrating on creating innovative treatment options, such as prodrug formulations, to enhance the bioavailability, effectiveness, and safety profiles of Parkinson’s disease therapies. Prodrugs are inert compounds that are metabolically transformed into active drugs within the body, enabling controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy leverages a soluble prodrug combination to ensure continuous levodopa delivery, aiming to diminish motor fluctuations and improve patients’ quality of life. The launch signifies a considerable advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and enhancing treatment adherence.
Who Are The Industry Participants Involved In The Neurodegenerative Disorder Therapeutics Market?
Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
Get The Full Neurodegenerative Disorder Therapeutics Market Report:
Which Region Is The Largest In The Neurodegenerative Disorder Therapeutics Market?
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neurodegenerative Disorder Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company
Neurology Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Interventional Neurology Devices And Equipment Market Report 2026
Neurosurgery Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
